- GlobeNewswire•2 days ago
DUBLIN, Ireland, Oct. 20, 2016-- Horizon Pharma plc, a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible ...
- CNW Group•4 days agoNuvo Pharmaceuticals™ Receives Approval from German Regulatory Authorities to Conduct Pennsaid® 2% Phase 3 Trial for Treatment of Acute Ankle Sprains
Nuvo Pharmaceuticals™ Receives Approval from German Regulatory Authorities to Conduct Pennsaid® 2% Phase 3 Trial for Treatment of Acute Ankle Sprains
- Moody's•5 days agoHorizon Pharma, Inc. -- Moody's Publishes Covenant Quality Assessment for Horizon Pharma, Inc. / Horizon Pharma USA, Inc.
New York, October 16, 2016-- Moody's Investors Service has assigned an overall covenant quality score of 4.39 to Horizon Pharma, Inc.' s $300 m _% Senior Notes due 2024. Subscribers can read the full report ...
Horizon Pharma plc (HZNP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||17.52 x 200|
|Ask||17.61 x 500|
|Day's Range||17.47 - 17.97|
|52wk Range||13.05 - 23.70|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-875.00|
|Avg Vol (3m)||3,574,066|
|Dividend & Yield||N/A (N/A)|